Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
REATA PHARMACEUTICALS INC (RETA)
|
Add to portfolio |
|
|
|
| Price: |
$27.32
| | Metrics |
| OS: |
37.6
|
M
| |
|
|
| Market cap: |
$1.03
|
B
| |
|
|
|
Net cash:
|
$321
|
M
| |
$8.55
|
per share
|
|
EV:
|
$705
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($385)
|
M
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 2.2 | 11.5 | 9.0 | 26.5 | 53.6 | 48.1 | 0.0 | 50.3 |
| Revenue growth | -80.7% | 27.4% | -66.0% | -50.5% | 11.5% | | -100.0% | -3.1% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 2.2 | 11.5 | 9.0 | 26.5 | 53.6 | 48.1 | 0.0 | 50.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | 100.0% |
| Selling, general and administrative | 280.3 | 256.2 | 235.3 | | | | | |
| Research and development | | | | 128.1 | 97.3 | 71.3 | 39.5 | 35.1 |
| General and administrative | | | | 58.3 | 32.7 | 23.3 | 16.6 | 13.7 |
| EBIT | -284.0 | -244.9 | -229.1 | -291.5 | -80.4 | -47.6 | -7.1 | -0.4 |
| EBIT margin | -12817.0% | -2131.3% | -2540.1% | -1099.2% | -150.1% | -99.1% | | -0.7% |
| Pre-tax income | -311.9 | -297.8 | -270.2 | -290.2 | -80.5 | -47.7 | -6.7 | -0.3 |
| Income taxes | 0.0 | -0.5 | -22.5 | 0.0 | 0.0 | 0.0 | -0.4 | 1.1 |
| Tax rate | 0.0% | 0.2% | 8.3% | | | | 6.6% | |
| Net income | -311.9 | -297.4 | -247.8 | -290.2 | -80.5 | -47.7 | -6.2 | -1.5 |
| Net margin | -14075.0% | -2588.2% | -2747.0% | -1094.3% | -150.3% | -99.2% | | -2.9% |
| |
| Diluted EPS | ($8.54) | ($8.19) | ($7.35) | ($9.54) | ($2.91) | ($1.99) | ($0.31) | ($0.09) |
| Shares outstanding (diluted) | 36.5 | 36.3 | 33.7 | 30.4 | 27.7 | 23.9 | 19.8 | 16.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|